Introduction : The idea of therapeutic fasting with healing virtues is circulating among cancer patients. Our study aims to improve knowledge of this practice, which is contraindicated in France during chemotherapy, and to establish recommendations to facilitate exchanges between doctors and patients.Methods : Chemotherapy patients completed a self-questionnaire on diet, therapeutic fasting and alternative medicine. A subsample of patients intending to follow dietary restrictions were interviewed.Results : Among the 133 participants, more than half had changed their diet and/or had heard of therapeutic fasting. Twenty-one patients intended to fast or have dietary restrictions during chemotherapy. These were mainly women, with an average age of 56 years, being treated for breast cancer, using alternative medications. They had little interaction with the health care team but would have liked to have had some with their oncologist. Nine patients were interviewed. They had tested short fasting and/or a ketogenic diet to improve treatment efficacy, reduce side effects and/or gain more control over their management. They did not dare to talk about it with the oncologist but regretted their silence. They are often advised by naturopaths and have tested homeopathy to accompany their treatment.Conclusions : Patients explain that they want to put all the odds in their favor. They would like the medical profession to offer times for discussion on fasting, silence being perceived as potentially harmful.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3917/spub.224.0481 | DOI Listing |
Cardiovasc Drugs Ther
January 2025
Department of Cardiothoracic Surgery, Affiliated Hospital of Nantong University, Nantong, 226000, Jiangsu, China.
Purpose: Cardiac inflammation is a basic pathological process of diabetic cardiomyopathy (DCM). Inflammatory response is closely related to pyroptosis, which is a recently identified programmed cell death type. Curcumin (CUR) is a polyphenol extracted from turmeric and has been reported to be crucial in alleviating pyroptosis in DCM.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute of Public and Preventative Health, Augusta, GA, USA.
Background: Physiological changes, including metabolic and cellular aging, as well as increased inflammation, occur in people living with dementia (PWD). While there is existing evidence in other populations suggesting that exercise may improve physiological outcomes, their impact in PWD remains unclear. This randomized controlled trial (RCT) aimed to assess the effects of exercise on serum levels of metabolic aging, cellular aging, and inflammatory blood biomarkers relative to usual care alone in PWD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Wake Forest Alzheimer's Disease Research Center, Winston-Salem, NC, USA.
Background: Diet composition is associated with neurodegenerative disease risk including Alzheimer's Disease (AD). The adverse effects of Western-style diets may be moderated, in part, by systemic as well as central inflammation, whereas the neuroprotective effects of Mediterranean diets may work through mechanisms that promote anti-inflammatory phenotypes. Systemic inflammation also may induce insulin resistance, another risk factor for AD.
View Article and Find Full Text PDFBackground: Interest and consumption of plant-based diets (PBD) in the 21 century continued to increase, particularly in western societies, with the perception that PBDs are associated with beneficial health outcomes and a reduced environmental footprint. Evidence suggests that PBDs may be protective against neurodegenerative diseases, such as Alzheimer's disease (AD). Health effects of PBDs such as reduction of inflammation, shift in gut microbiota composition, reduced risk of type 2 diabetes and cardiovascular disease are all believed to attribute to reduced AD risk.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
AriBio Co., Ltd., Seongnam, Korea, Republic of (South).
Background: AR1001 is a specific inhibitor of phosphodiesterase-5 (PDE5), which degrades cyclic guanosine monophosphate (cGMP). cGMP/cAMP response element-binding protein (CREB)/brain-derived neurotrophic factor (BDNF) signaling, which is critical for learning and memory processes, is disturbed in Alzheimer's disease (AD). AR1001 at the oral dose of 30 mg QD is currently in a global Phase 3 clinical trial in early AD patients (NCT05531526).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!